Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
REGULATORY
Top MHLW Bureaucrat Hints Party Debate Will Affect Fate of Off-Year Revision
Kazuhito Ihara, vice minister for health, labor and welfare, on November 8 aired his ministry’s intention to look at political debates in negotiating the “off-year” drug price revision with counterparts at the Ministry of Finance (MOF). “Based on the discussions…
To read the full story
REGULATORY
- Japan Panel OKs Listing of Kisunla, Tepezza, Quviviq, and Many More
November 14, 2024
- Xocova Price to Be Trimmed by 300 Yen after CEA; No Change for Mounjaro
November 14, 2024
- Draft Economic Package Embraces Measures to Ensure Stable Generic Supply
November 13, 2024
- DPP to Ruling Bloc: Quickly Scrap Off-Year Drug Price Revisions
November 13, 2024
- Ex-LDP Bigwig Kamoshita Urges Pharma Industry to Speak Up More
November 13, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…